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Cyclooxygenase-2 inhibitors (coxibs) are characterized by multiple molecular off-target effects and 
increased coronary artery disease (CAD) risk. Here, we systematically explored common variants of 
genes representing molecular targets of coxibs for association with CAD. Given a broad spectrum of 
pleiotropic effects of coxibs, our intention was to narrow potential mechanisms affecting CAD risk as 
we hypothesized that the affected genes may also display genomic signals of coronary disease risk. 
A Drug Gene Interaction Database search identified 47 gene products to be affected by coxibs. We 
traced association signals in 200-kb regions surrounding these genes in 84,813 CAD cases and 202,543 
controls. Based on a threshold of 1 × 10−5 (Bonferroni correction for 3131 haplotype blocks), four 
gene loci yielded significant associations. The lead SNPs were rs7270354 (MMP9), rs4888383 (BCAR1), 
rs6905288 (VEGFA1), and rs556321 (CACNA1E). By additional genotyping, rs7270354 at MMP9 and 
rs4888383 at BCAR1 also reached the established GWAS threshold for genome-wide significance. The 
findings demonstrate overlap of genes affected by coxibs and those mediating CAD risk and points 
to further mechanisms, which are potentially responsible for coxib-associated CAD risk. The novel 
approach furthermore suggests that genetic studies may be useful to explore the clinical relevance of 
off-target drug effects.
1Institute for Cardiogenetics, University of Lübeck, 23562, Lübeck, Germany. 2DZHK (German Research Center for 
Cardiovascular Research), partner site Hamburg/Lübeck/Kiel, 23562, Lübeck, Germany. 3University Heart Center 
Lübeck, 23562, Lübeck, Germany. 4Department of Cardiology, Division Heart and Lungs, University Medical Center 
Utrecht, 3584, Utrecht, The Netherlands. 5Deutsches Herzzentrum München, Technische Universität München, 
80636, München, Germany. 6University of Michigan, Dept of Biostatistics, 1415 Washington Hts, Ann Arbor, MI, 
48104, USA. 7Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University 
Hospital, 70210, Kuopio, Finland. 8Preventive Cardiology and Preventive Medicine, Center for Cardiology, University 
Medical Center Mainz, Mainz, Germany. 9Center for Thrombosis and Hemostasis, University Medical Center 
Mainz, Mainz, Germany. 10DZHK (German Center for Cardiovascular Research), Partner Site RhineMain, Mainz, 
Germany. 11Department of General and Interventional Cardiology, University Heart Center Hamburg-Eppendorf, 
Hamburg, Germany. 12Uppsala Clinical Research Center, Uppsala Science Park, MTC, SE-752 37, Uppsala, Sweden. 
13Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University, Skåne University 
Hospital Malmö, Malmö, Sweden. 14THL-National Institute for Health and Welfare, POB 30, Mannerheimintie 
166, FI-00271, Helsinki, Finland. 15Department of Epidemiology, Erasmus University Medical Center, 3000 CA, 
Rotterdam, The Netherlands. 16Institute of Human Genetics, Helmholtz Zentrum München, German Research 
Center for Environmental Health, 85764, Neuherberg, Germany. 17DZHK (German Center for Cardiovascular 
Research), partner site Munich Heart Alliance, 80636, Munich, Germany. 18Institute of Human Genetics, Technische 
Universität München, 81675, Munich, Germany. 19Deparment of Cardiovascular Sciences University of Leicester and 
NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, LE3 9QP, UK. 20Institute of 
Cardiovascular Science, faculty of Population Health Sciences, University College London, London, United Kingdom. 
Correspondence and requests for materials should be addressed to J.E. (email: jeanette.erdmann@uni-luebeck.de)
Received: 16 March 2017
Accepted: 16 August 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIentIfIC REpoRTs | 7: 10252  | DOI:10.1038/s41598-017-10928-4
Selective COX-2 inhibitors (coxibs) display non-steroidal anti-inflammatory effects, which are widely used 
to treat chronic pain syndromes. However, long-term administration of coxibs has been found consistently to 
increase risk of cardiovascular events including myocardial infarction and coronary death1. Given such severe 
adverse effects, their use is controversially discussed in the United States and Europe2. In fact, several coxibs, such 
as rofecoxib, have been withdrawn from the marked for that reason3.
The recently published PRECISION trial evaluated the cardiovascular safety of celecoxib and reported no 
increased risk as compared to two nonselective NSAID4. However, the results have been controversially dis-
cussed for a number of reasons5, 6. For example, almost 70% stopped taking the medication during the two years 
of follow-up, which was entirely lost in about 25% patients4. Moreover, celecoxib was somewhat less effective 
than its comparators; most likely due to the relatively low dose of celecoxib used in this trial (about 200 mg/
day). By contrast, studies that have shown an increase of coronary risk used higher doses (400–800 mg). Perhaps 
most importantly, the variants identified in our study are located in genes that are downstream of COX2 and 
thus affected in a similar way by the three drugs tested. Hence, our data may be relevant for NSAID in general 
and add to the long standing discussion of the underlying mechanisms related to both intended (analgesic) and 
unintended (cardiovascular) effects.
Their principle mechanism of action is to selectively inhibit the cyclo-oxygenase 2 isoform (COX-2) to reduce 
prostaglandin I2 and prostacyclin pro-inflammatory effects. In contrast to non-selective Cox-inhibitors, coxibs 
do not lower COX-1 derived thromboxane production. Since thromboxane activates platelets, selective Cox-2 
inhibitors may affect unfavorably the prostacyclin (antithrombotic)/thromboxane (prothrombotic) ratio, which 
may explain their thrombo- and atherogenicity, and their blood pressure increasing effects3. However, coxibs 
display numerous other (pleiotropic or off-target) effects, which likewise could add to the untoward safety profile 
of the drugs3. For example, coxibs may suppress NO production, which has been related to CAD risk by genetic 
means7. Moreover, other Cox-inhibitors not affecting the prostacyclin/thromboxane ratio may also increase 
coronary event rates2. Thus, the precise mechanisms explaining cardiovascular risks of coxibs are not proven 
definitively2.
Genetic variants affecting disease risk can facilitate identification of drug targets8, 9. Likewise, variants may 
point to potential adverse effects, if risk alleles and drugs have similar functional implications10, 11. Here, we 
reversed this approach and systematically explored known molecular targets of coxibs for signals in genome-wide 
association studies (GWAS) on CAD.
The starting point of our analysis was to identify genes or gene products reported in the Drug Gene 
Interaction Database12 to interact with coxibs. Considering all genes interacting with coxibs we aimed to filter 
out those with the potential to affect the CAD risk related to these drugs specifically by searching respective 
genes for genomic signals indicating CAD risk. The underlying idea is that single nucleotide polymorphisms 
(SNPs) may mimic drug effects in disturbing the function or regulation of a gene product, and therefore – 
like the drug – associate with CAD risk, even if the effect sizes might vary. The enormous statistical power of 
contemporary genomic analyses was thereby used to scrutinize the spectrum of pleiotropic coxib effects for 
those that may contribute to the increased CAD risk of long-term users of these frequently prescribed drugs. 
Remarkably, the strategy also led to successful identification of novel variants genome-wide significantly asso-
ciated with CAD risk.
Methods
The principle approach taken in this study is illustrated in Fig. 1. The first step of the pipeline was to identify genes 
or gene products reported to interact with coxibs. For this we downloaded the Drug Gene Interaction Database 
version 2.22 (DGIdb)12. This database aims to capture genes that are known to be targeted by drugs. It is rather 
inclusive in that liberal criteria are used to allow entry in this database12. Thus, it may also include gene or gene 
products with relatively weak evidence for drug interaction. Despite this noise, we decided not to perform any 
manipulation on the database to avoid a bias introduced by a priori hypothesis. With this strategy, we expect that 
at least some of the genes reported in the database reflect true interactions which are interesting for genetic inter-
rogation of coxib-related cardiovascular side effects.
We included all genes reported to interact with celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, and 
valdecoxib. The genes reported in DGIdb are shown in supplementary Table 2. This table also shows the complete 
output of the DGIdb query. We identified all SNPs within 200-kb surrounding the genes whose products are 
affected by these drugs. The 200-kb window was selected to capture most genetic variants with potential regula-
tory effects.
GWAS datasets. Having identified the drug gene interactions, we subsequently screened respective 
genes for association signals in the CARDIoGRAMplusC4D 1000 G GWAS meta-analysis on CAD13 and addi-
tional non-overlapping datasets from CARDIoGRAM14 and German MI Family Studies V (GerMIFS V). The 
CARDIoGRAMplusC4D 1000Genomes meta-analysis data set consists of 47 GWAS studies including data 
from 60,801 cases and 123,504 controls. The GWAS are imputed with the 1000Genomes phase I integrated 
haplotypes from December 2012 (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/) (for Methods 
see Nikpay et al.13).
We combined this data set13 with GWAS from CHARGE15, deCODE CAD16, CADomics14, DILGOM17, EPIC7, 
FRISC II GLACIER18, METISM19, MORGAM FIN20, MORGAM FRA20, MORGAM GER20, MORGAM ITA20, 
MORGAM UNK20, PMB7, PopGen21, SCARF SHEEP7, and STR22 that have been previously reported in refer-
ences Schunkert et al.14 and/or Deloukas et al.7. Moreover, we included data from GWAS not reported before, i.e. 
GerMIFS V. See detailed information in supplementary Table 1. In total, this combined dataset consists of 84,813 
cases and 202,543 controls.
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The SNPs identified in the first stage of analysis were genotyped in additional 2,496 cases and 1,505 controls 
from the GerMIFS VI study (unpublished).
Statistical Methods. In the exploratory analysis of SNPs, we assumed significance for association with CAD 
after Bonferroni correction for the number of independent SNPs tested. We calculated the number of independ-
ent SNPs based on the linkage disequilibrium (LD) between SNPs. This method is analogue to the one pro-
posed by Nyholt23. Nyholt et al. proposed a method to correct for multiple testing based on pairwise LD between 
SNPs. Because Nyholts approach, which uses spectral decomposition of pairwise LD matrices, is computationally 
demanding, we correct using the number of haplotype blocks. The number of independent SNPs was estimated 
based on the number of haplotype blocks calculated with PLINK software using the default setting of the blocks 
command. We calculated the haplotype blocks using the GerMIFS IV study. We do not have individual genotype 
data from all studies but expect this GWAS to be representative. For a total of 81,703 SNPs within the 47 gene 
regions tested, we identified 3,131 haplotype blocks and defined significance according to Bonferroni at a p-value 
threshold of 1 × 10–5.
Meta-analysis. Logistic regression, assuming an additive model, was performed on all single study data. We 
performed logistic regression with all genotype data available. Individuals with no genotype data or with poor 
quality genotype data were excluded from regression analysis. All analyses were adjusted for sex and age. Age 
was defined as the recruitment age for controls and the event age for cases. For meta-analysis, we calculated an 
‘inverse variance weighting’- fixed-effects and a random effects model24, depending on the heterogeneity between 
the studies. For heterogeneity calculation Cochran’s Q was used. Threshold for heterogeneity was phet <0.01. 
We combined the CARDIoGRAMplusC4D 1000Genomes meta-analysis data set and non-overlapping 
CARDIoGRAM, GerMIFS V, and GerMIFS VI studies using an ‘inverse variance weighting’-fixed-effects model 
and combined effects and p-values were reported. In total we evaluated the genomic data from 87,309 CAD 
patients and 204,048 controls.
Functional annotation of SNPs and genes. To evaluate the functional implication of the SNPs, we iden-
tified all SNPs with an LD of r2 > 0.8 to the locus lead SNP using the HaploReg version 3 database25. We then used 
the Cardiogenics data set26 for a systematic search for expression quantitative trait loci (eQTLs) affecting mono-
cyte and macrophage expression, the publicly available data from Westra et al.27, GTeX28 and over 100 studies 
included in the Genome-Wide Repository of Associations between SNPs and Phenotypes (GRASP) database29. In 
addition, we used HaploReg25 to locate SNPs in promoter and enhancer regions and performed a literature search 
for gene functions using Pubmed.
Figure 1. Experimental Strategy: 1. Cox 2 inhibitors (coxibs) are known to increase coronary risk. 2. All genes 
known to be targets of coxibs were extracted from the Drug-Gene Interaction Database (DGIdb). 3. DGIdb 
revealed 47 genes that interact with coxibs. 4. All common variants at the chromosomal regions representing the 
47 genes were subjected to a large-scale association study. 5. Four genes displayed significance for association 
with CAD risk. 6. These genes are candidate risk genes for CAD. 7. It may be hypothesized that the genes 
affected by coxibs and here shown to associate with CAD risk participate in the adverse effects of the drugs. 
Some drawings were obtained and used under license from Shutterstock.com (https://www.iconfinder.com/
licenses/basic). Images can be found under: https://www.shutterstock.com/image-vector/chromosomes-vector-
icon-style-flat-symbol-323629910?src=library, https://www.shutterstock.com/image-vector/organ-heart-
icon-310580756, https://www.shutterstock.com/image-vector/dna-icon-397249525, https://www.shutterstock.
com/image-vector/pills-medication-vector-icons-set-131402543?src=library, https://www.iconfinder.com/
icons/240302/find_computer_find_desktop_look_for_desktop_search_search_desktop_icon#size=128.
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Identification of pleiotropic cardiovascular effects of SNPs. We used the GRASP database to screen 
for association signals for CAD-related phenotypes at the four loci displaying association with CAD. The GRASP 
database contains the association results of around 1,390 GWAS29 and is the most comprehensive GWAS data-
base. We searched for reported associations with CAD-related traits in the GRASP database for all SNPs with LD 
of r2 > 0.8 with the lead SNPs. We used p < 1 × 10−3 for CAD-related traits to avoid false positive associations.
Test for enrichment. To test for enrichment, we downloaded the GSEA curated pathways database 
(MSigDB version c2.cp.v5.1)30 which comprises a total of 1330 pathways. We compared the number of eSNPs 
displaying a significant effect – after the Bonferroni correction p < 1 × 10−5 as used in our main analysis – for 
CAD risk in these pathways with respective eSNPs within the coxib gene subset using the Fisher exact test. SNPs 
were annotated the using the publicly available eQTL databases listed above.
Results
We identified in the publicly available Drug Gene Interaction Database 47 genes or gene products to interact with 
coxibs12 (supplementary Table 2). We studied the 200-kb region surrounding respective genes in a combined 
1000Genomes imputed meta-analysis (data from CARDIoGRAM and CARDIoGRAMplusC4D) to search for 
SNPs showing association with CAD13. Correcting for multiple testing accounting for haplotype blocks, we con-
sidered SNPs significant with a p-value lower than 1 × 10−5. In this way, we revealed a total of four loci associated 
with CAD (Table 1 and Fig. 2 and supplement Table 3).
In the coxib pathway we identified 43 genes out of which 3 (or 7%) were found to have eSNPs displaying a 
significant effect – after Bonferroni correction p < 1 × 10−5 – for CAD risk. For comparison, in GSEA curated 
pathways out of 7076 genes only 1.5% of genes had respective eSNPs with a comparable signal for CAD risk. 
Figure 2. Association signals for at the chromosomal regions of coxib genes (A) MMP9, (B) BCAR1, (C) 
CACNA1E, and (D) VEGFA using Locus Zoom53.
Gene Lead SNP
CAD risk 
allele
Frequency 
risk allele
OR risk 
allele P-value
P-value combined 
analysis
Relationship of coxib to 
gene/gene product*
Regulatory effect 
(Histone marks)
BCAR1 rs4888383 T 0.57 1.05 7.99*10−08 2.98*10−08 inhibition Promoter/Enhancer
MMP9 rs7270354 A 0.15 1.06 6.75*10−08 3.34*10−08 decreased expression Promoter/Enhancer
VEGFA rs6905288 A 0.60 1.04 7.44*10−07 8.86*10−07 decreased expression Enhancer
CACNA1E rs556321 C 0.16 1.05 8.26*10−06 8.85*10−06 inhibition Promoter/Enhancer
Table 1. Association signals for CAD within 200 kb of genes reported for coxib/gene product interactions. For 
each gene, the lead SNP is shown. The regulatory effects were annotated using Haploreg25.
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Hence, the set of genes on which our approach was focused was significantly enriched – by Fisher exact p-value 
of 0.03 – for genes with an eSNPs showing a signal for CAD.
The genes affected by coxibs and located within the loci showing SNP association for CAD are the vascular 
endothelial growth factor A (VEGFA), matrix metalloproteinase-9 (MMP9), breast cancer anti-estrogen resist-
ance protein 1 (BCAR1) and the calcium channel, voltage-dependent, R type, alpha 1E subunit (CACNA1E). For 
the lead SNPs tagging these genes, we performed additional genotyping of 2,496 cases and 1,505 controls.
The A allele of the VEGFA lead SNP, rs6905288, is associated with CAD with a p-value of p = 8.86 × 10−7 
(OR 1.04) in our data. In the GRASP database, this SNP shows genome-wide significant association with waist 
hip ratio and suggestive association with HDL cholesterol level, triglycerides, and systolic and diastolic blood 
pressure, respectively (for references and further information please see the supplement Table 4). The lead SNP is 
found in enhancer regions, and is associated with a decreased expression of VEGFA in adipose tissue31.
The A allele of the MMP9 lead SNP, rs7270354, is located upstream of the gene and is genome-wide signifi-
cantly associated with CAD (p = 3.34 × 10−8, OR 1.06). The lead SNP and linkage disequilibrium (LD) SNPs are 
found in enhancer regions in several cell types. However, neither this SNP nor a SNP in LD (r2 > 0.8) is associated 
with another CAD related phenotype in GRASP. The CAD risk allele is associated with increased expression of 
MMP9 in whole blood27. The effect of the CAD risk allele is opposite of the effect of coxibs on the gene. However, 
it is well established that SNPs showing eQTL effects, can have opposite effect in different tissues32. Hence, the 
identified eQTL effect demonstrates the regulatory effect of the SNP on MMP9. Further studies are needed to 
identify the effect of this SNP in CAD relevant tissue as for instance smooth muscle cells.
Lead SNP, rs4888383, is located upstream of the gene BCAR1 and shows genome-wide significant association 
with CAD (p = 2.98 × 10−8, OR T 1.05). SNP rs4888383 is located in a potentially functional promoter region, 
with the CAD risk allele (T), and SNPs in high LD (r2 > 0.8), being linked to reduced expression of BCAR1 in the 
esophagus mucosa (GTeX). The LD SNP rs4888378, was previously associated with carotid intima media thick-
ness (p = 6.5 × 10−7) and CAD (p = 6.53 × 10−6). In addition, the lead SNP shows suggestive association with 
systolic and pulse pressure, urinary albumin to creatinine ratio, and microalbuminuria (for references and further 
information please see supplementary Table 4).
Figure 3. Pharmacodynamic effects of coxib treatment related to the genetic association signals. All SNPs and 
their functional implication are shown based on the CAD risk allele. The rs numbers indicate the lead SNPs 
and their hypothesized function. rs6905288 is strongly associated with waist-to-hip-ratio and rs7202877 with 
type 1 diabetes (T1D). Suggestive associations were reported for rs4888383 with carotid intima media thickness 
(CIMT) and systolic blood pressure (SBP), for rs6905288 with hypertension (HTN), HDL-cholesterol, and 
triglycerides (TG), and for rs556321 with obesity (OB) and blood metabolites (BM). CAD risk allele rs556321 
is associated with decreased expression of CACNA1E, rs4888383 is associated with decreased expression of 
BCAR1 and rs6905288 is associated with decreased expression of VEGFA. Functional links: ↑ (induction),  
┬ (inhibition), ║(unknown effect). Dotted lines indicate potential intermediate functional link. AA: arachidonic 
acid, COX-2: Cyclooxigenase-2, PGE2: prostaglandin E2, VEGFA: vascular endothelial growth factor A, MMP9: 
matrix metalloproteinase-9, BCAR1: breast cancer anti-estrogen resistance protein 1, CACNA1E: calcium 
channel, voltage-dependent, R type, alpha 1E subunit. PD: Plaque disruption, MS = Metabolic Syndrome, T1D: 
type 1 diabetes, CIMT: carotid intima media thickness, SBP: systolic blood pressure, HTN: hypertension, HDL: 
HDL-cholesterol, TG: triglycerides, OB: obesity, BM: blood metabolites. For references see supplement.
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The C allele of the CACNA1E lead SNP, rs556321, and several LD SNPs span the promoter of the gene. It is 
associated with CAD with a p-value of p = 8.85 × 10−6 (OR 1.05). Genetic variants in CACNA1E are reported to 
play a role in hypertension. LD SNPs of rs556321 are associated with blood metabolite concentrations and obesity. 
The CAD risk allele is associated with decreased expression of CACNA1E in blood (for references and further 
information see supplementary Table 4).
Figure 3 integrates the four genes in the functional pathways affected by coxib administration. It illustrates 
that VEGFA and MMP9 are downstream of the principle mechanism of COX-2 inhibition and thus may repre-
sent a class effect. BCAR1 and CACNA1E are not related to the intended pharmacological action and may thus 
represent off-target effects.
Discussion
A data-base on drug-gene interactions lists 47 genes or gene products to be affected by administration of cox-
ibs12, a class of drugs known for prominent coronary side effects. Analysis of the chromosomal loci harboring 
respective genes identified two novel loci with genome-wide significant association and two loci with robust 
association signals for CAD. In conjunction, it appears that coxibs affect several gene products that also play a 
role in modulating genetic risk of CAD. With respect to the pharmacological profile of coxibs, these data point 
to potential novel mechanisms for the increased myocardial infarction risk observed in long-term users of this 
medication.
The reason for the multitude of genes affected by inhibition of COX-2 relates in part to the variety of down-
stream signaling events caused by reduction of prostaglandin synthesis. VEGFA and MMP9 may be involved via 
this primary drug effect. BCAR1 may be affected by coxibs via other, pleiotropic mechanisms, but – like VEGFA 
and MMP9 – this gene has been studied functionally in the context of atherosclerosis before33–36. Thus, detection 
of robust genetic signals for association with CAD within these genes appears to be plausible.
Celecoxib is reported to suppress the expression of VEGFA37. VEGFA is an important signaling molecule that 
mediates vasculogenesis, angiogenesis, and vascular maintenance38. VEGFA furthermore augments NO levels 
and, hence, may ameliorate platelet aggregation and vasoconstriction39. Inhibition of VEGFA is reported to lead 
to hypertension35. The lead SNP at the VEGFA locus showed multiple associations with coronary risk factors 
further corroborating its role in CAD.
Celecoxib is reported to inhibit the production of MMP9 in several cell types40. MMP9 is a zinc-dependent 
endopeptidase with tissue-specific expression known to up-regulate VEGFA34, 41. On the other hand, higher levels 
of MMP9 have been reported in patients with CAD33 and metabolic syndrome42. In addition, MMP9 has been 
linked with hypertension43, arterial stiffness43 and is reported to induce acute plaque disruption44. Further, MMP 
activation has been related to decreased aortic elasticity in mice via prostaglandin E2 receptor signaling45.
Celecoxib is reported to inhibit BCAR146 which belongs to the CAS family of scaffolding proteins substrate 
and is often linked to several forms of cancer47. In addition, the gene is reported to be associated with focal 
adhesions, regulation of smooth muscle cell migration, carotid intima media thickness and CAD48. It appears to 
be activated downstream through the angiotensin II pathway49. Interestingly, BCAR1 overexpression has been 
associated with celecoxib resistance in colorectal cancer46.
Celecoxib is reported to inhibit L-type calcium channels in a COX-2 independent pathway50. CACNA1E 
mediates the cell surface membrane potential and affects several cellular processes such as contraction and 
gene expression51. The lead SNP at the CACNA1E locus showed associations with other coronary risk factors. 
CACNA1E inhibition is also reported to lead to hypertension36 and hence, as VEGFA, is a strong candidate to 
explain the CAD risk of coxibs. The CAD risk SNP representing the CACAN1E locus is associated with reduced 
expression of the gene, which matches with the direction of effect reported for coxibs.
Taken together, our data indicate mechanistic parallelisms between chronic intake of coxibs and genetic var-
iants affecting CAD risk, both being diverse. In line with our principle observations, we also find a large overlap 
of coxib related side effects and the traits related to the SNPs (see supplement Table 5). The four genes, identified 
in this study to associate genetically with CAD risk, are all reported to interact with celecoxib in the DGIdb. The 
other coxibs, however, might also alter these genes, without being studied in detail so far. Especially MMP9 and 
VEGFA, downstream of COX-2, are likely to be affected by the other coxibs.
On the cellular level, coxibs have been implicated to modulate angiogenesis, inflammation, cell cycle arrest, 
and apoptosis52, as well as focal adhesions and vascular tone50. The interaction between coxibs and the genes 
associated with CAD by our investigation may reinforce the implications of some of the adverse mechanisms 
affected by the drugs. Indeed, given the association findings reported in this study it appears plausible that the 
increased CAD risk is also mediated by mechanisms other than disturbing the prostacyclin/thromboxane ratio. 
While VEGFA and MMP9 are both downstream COX-2 inhibition, BCAR1 and CACNA1E are affected presum-
ably through independent pathways.
In this work, we defined the risk alleles as those found more frequently in CAD cases. The definition is not 
based on functional testing and defining the allele more frequently found in controls as protective would be 
equally valid. However, exploring publically available data bases we observed genotype specific differences in 
gene expression which might relate to the mechanistic effects. We assigned the SNPs to VEGFA, MMP9, BCAR1, 
and CACNA1E because these were the genes altered by coxibs and because the SNPs are eQTLs for the respec-
tive genes. It is, however, possible that the SNPs have effects on other genes as well. Indeed, we have previously 
demonstrated that regulatory SNPs influence the expression of multiple genes32. Hence, we do not exclude other 
genes to mediate the effect on CAD for the identified loci.
Our study design has several limitations. All our findings are based on associations rather than functional 
testing. Here we did not test formally whether the effects of coxibs and risk alleles on respective gene products 
have identical directionality. This may be particularly evident, as we cannot always derive the directionality of the 
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SNPs on expression levels of the genes that are considered as intermediary phenotypes. However, functional tests 
reported in the literature, as described above, are consistent with the genetic evidence provided here. Finally, we 
have no information in the large CARDIoGRAMplusC4D database on the intake of pain relieving medication 
prior to the manifestation of coronary disease. Since the association is depending on the genotype, drugs or other 
confounding factors are unlikely to inflate the findings. To have an effect on the association, the administration 
or the metabolism of the drug has to also depend on the genotype. We cannot completely exclude a pleiotropic 
effect, but we consider it to be very unlikely. Given the conclusive nature of the association findings, first between 
coxibs and CAD risk2, second between coxibs and respective gene products12, and third, between genetic variants 
at respective loci and CAD risk reported here, the data are highly plausible. Particularly, the strength of associ-
ation with genome-wide significance for some of the gene variants may be considered to be sufficient even in a 
hypothesis-free analysis.
Taken together, pleiotropic or off-target effects are responsible for some adverse effects of drugs. Studying all 
genes known to be affected by coxibs, a class of drugs related to a prominent coronary risk, we have identified 
genomic mediators of CAD risk. The effects of coxibs on these genes might contribute to the unsatisfactory safety 
profile of this frequently used medication. Last, by exploring the mechanisms underlying the coxibs adverse 
effects, we revealed genome-wide significant associations for increased risk CAD at two genomic loci.
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